Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?

Neuromuscular Disorders

Volumn 15, Issue 6, 2005, Pages 399-402

  Wilton, Steve D ^a   Fletcher, Susan ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DYSTROPHIN;

CLINICAL TRIAL; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; EXON; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INTRON; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; RNA SPLICING; SIDE EFFECT; STOP CODON; THROMBOCYTOPENIA; WESTERN BLOTTING;

GENE THERAPY; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE;

EID: 19344362163     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2005.03.003     Document Type: Editorial

References (24)

1. M. Koenig, E.P. Hoffman, C.J. Bertelson, A.P. Monaco, C. Feener, and L.M. Kunkel Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals Cell 50 1987 509 517
2. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome Nature 431 2004 931 945
3. M.C. Wollerton, C. Gooding, E.J. Wagner, M.A. Garcia-Blanco, and C.W. Smith Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay Mol Cell 13 2004 91 100
4. A. Aartsma-Rus, M. Bremmer-Bout, A.A. Janson, J.T. den Dunnen, G.J. van Ommen, and J.C. van Deutekom Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy Neuromuscul Disord 12 Suppl. 1 2002 S71 S77
5. M.G. Dunckley, M. Manoharan, P. Villiet, I.C. Eperon, and G. Dickson Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides Hum Mol Genet 7 1998 1083 1090
6. S.D. Wilton, F. Lloyd, and K. Carville Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides Neuromuscul Disord 9 1999 330 338
7. E.R. Barton-Davis, L. Cordier, D.I. Shoturma, S.E. Leland, and H.L. Sweeney Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice J Clin Invest 104 1999 375 381
8. M.T. Howard, C.B. Anderson, and U. Fass Readthrough of dystrophin stop codon mutations induced by aminoglycosides Ann Neurol 55 2004 422 426
9. L. Politano, G. Nigro, and V. Nigro Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results Acta Myol 22 2003 15 21
10. K.R. Wagner, S. Hamed, and D.W. Hadley Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations Ann Neurol 49 2001 706 711
11. M. Fanin, M.P. Freda, L. Vitiello, G.A. Danieli, E. Pegoraro, and C. Angelini Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: threshold effect for deletion size? Muscle Nerve 19 1996 1154 1160
12. J. Summerton Morpholino antisense oligomers: the case for an RNase H-independent structural type Biochim Biophys Acta 1489 1999 141 158
13. T.L. Jason, J. Koropatnick, and R.W. Berg Toxicology of antisense therapeutics Toxicol Appl Pharmacol 201 2004 66 83
14. X.P. Ioannou, S.M. Gomis, B. Karvonen, R. Hecker, L.A. Babiuk, and S. van Drunen Littel-van den Hurk CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein Vaccine 21 2002 127 137
15. S. Agrawal Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides Biochim Biophys Acta 1489 1999 53 68
16. C.J. Mann, K. Honeyman, and A.J. Cheng Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse Proc Natl Acad Sci USA 98 2001 42 47
17. Q.L. Lu, C.J. Mann, and F. Lou Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse Nat Med 9 2003 1009 1014
18. Q.L. Lu, A. Rabinowitz, and Y.C. Chen Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles Proc Natl Acad Sci USA 102 2005 198 203
19. J. Marshall, H. Chen, and D. Yang A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann Oncol 15 2004 1274 1283
20. R. Advani, P. Peethambaram, and B.L. Lum Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma Cancer 100 2004 321 326
21. S. Paul Technology evaluation: CpG-7909, Coley Curr Opin Mol Ther 5 2003 553 559
22. M.C. Cripps, A.T. Figueredo, and A.M. Oza Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study Clin Cancer Res 8 2002 2188 2192
23. A.A. Chanan-Khan Bcl-2 antisense therapy in multiple myeloma Oncology (Huntingt) 18 2004 21 24
24. J.S. Cohen Informational drugs: a new concept in pharmacology Antisense Res Dev 1 1991 191 193